Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02651714 · ClinicalTrials.gov registry record · Phase 2
Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis
A Phase 2 study of Atopic Dermatitis, sponsored by Vanda Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 168
- Enrollment target
- 20
- Study locations
NCT02651714 is a Phase 2 study of Atopic Dermatitis that has completed, run by Vanda Pharmaceuticals. The registered enrollment target is 168 participants, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (72% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT02651714, a Phase 2 study of Atopic Dermatitis, has completed, sponsored by Vanda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 168 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with treatment-resistant pruritus diagnosed with atopic dermatitis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tradipitant
Study Locations (20)
California
- Vanda Investigational Site - Encinitas
- Vanda Investigational Site - Encino
- Vanda Investigational Site - Lomita
- Vanda Investigational Site - San Diego
- Vanda Investigational Site - San Diego
Florida
- Vanda Investigational Site - Miami
- Vanda Investigational Site - Miami
- Vanda Investigational Site - Ormond Beach
North Carolina
- Vanda Investigational Site - High Point
- Vanda Investigational Site - Wilmington
- Vanda Investigational Site - Winston-Salem
New York
- Vanda Investigational Site - New York
- Vanda Investigational Site - New York
Georgia
- Vanda Investigational Site - Columbus
Indiana
- Vanda Investigational Site - Plainfield
Louisiana
- Vanda Investigational Site - Crowley
Missouri
- Vanda Investigational Site - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2016-01-19 |
| Est. Completion | 2017-08-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02651714
The ClinicalTrials.gov registry entry for NCT02651714 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (72% lower). The listed sponsor is Vanda Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02651714 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, North Carolina.
Frequently Asked Questions
What is clinical trial NCT02651714 about?
NCT02651714 is a clinical study titled "Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis". This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with treatment-resistant pruritus diagnosed with atopic dermatitis.
What is the current status of trial NCT02651714?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 168 participants. The study started on 2016-01-19. Estimated completion is 2017-08-04.
What conditions does trial NCT02651714 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT02651714?
The interventions under investigation include: Placebo (DRUG), Tradipitant (DRUG).
Who is sponsoring clinical trial NCT02651714?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02651714 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Indiana, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study Evaluating TRIV-509 in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.